Raludotatug deruxtecan has received breakthrough therapy designation for treatment of certain adults with platinum-resistant epithelial ovarian cancer , primary peritoneal or fallopian tube cancers that express CDH6 .

This indication applies to adults previously treated with bevacizumab (Avastin, Genentech), according to a press release.

Raludotatug deruxtecan has received breakthrough therapy designation for treatment of certain adults with platinum-resistant epithelial ovarian cancer, primary peritoneal or fallopian tube cancers that express CDH6.

Raludotatug deruxtecan (Merck, Daiichi Sankyo) — an investigational, first-in-class CDH6 directed antibody-drug conjugate — received FDA breakthrough therapy designation based on data from two clinical trials. The first is a two-part,

See Full Page